[1]
|
Dawson, T.M., Dawson, V.L. (2003) Molecular pathways of neurodegeneration in Parkinson’s disease. Science, 302, 819-822. doi:10.1126/science.1087753
|
[2]
|
Ross, C.A., Smith, W.W. (2007) Gene-environment in- teractions in Parkinson’s disease. Parkinsonism & Re- lated Disorders, 13, S309-S315.
doi:10.1016/S1353-8020(08)70022-1
|
[3]
|
Dick, F.D. (2006) Parkinson’s disease and pesticide ex- posures. British Medical Bulletin, 79-80, 219-231.
doi:10.1093/bmb/ldl018
|
[4]
|
Hoglinger, G.U., Oertel, W.H. and Hirsch, E.C. (2006) The rotenone model of parkinsonism—The five years in- spection. Journal of Neural Transmission, 70, 269-272. doi:10.1007/978-3-211-45295-0_41
|
[5]
|
Sherer, T.B., Betarbet, R., Stout, A.K., Lund, S., Baptista, M., Panov, A.V., Cookson, M.R. and Greenamyre, J.T. (2002) An in vitro model of Parkinson’s disease: Linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. The Journal of Neuro- science, 22, 7006-7015.
|
[6]
|
Betarbet, R., Canet-Aviles, R.M., Sherer, T.B., Mastro- berardino, P.G., McLendon, C., Kim, J.H., Lund, S., Na, H.M., Taylor, G. and Bence, N.F. (2006) Intersecting pathways to neurodegeneration in Parkinson’s disease: Effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiology of Disease, 22, 404-420. doi:10.1016/j.nbd.2005.12.003
|
[7]
|
Betarbet, R., Sherer, T.B., MacKenzie, G., Garcia-Osuna, M., Panov, A.V. and Greenamyre, J.T. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nature Neuroscience, 3, 1301-1306.
doi:10.1038/81834
|
[8]
|
Coulom, H. and Birman, S. (2004) Chronic exposure to ro- tenone models sporadic Parkinson’s disease in Drosophila melanogaster. The Journal of Neuroscience, 24, 10993-10998. doi:10.1523/JNEUROSCI.2993-04.2004
|
[9]
|
Hosamani, R., Ramesh, S.R. and Muralidhara. (2010) Attenuation of rotenone-induced mitochondrial oxidative damage and neurotoxicty in Drosophila melanogaster supplemented with creatine. Neurochemical Research, 35, 1402-1412. doi:10.1007/s11064-010-0198-z
|
[10]
|
Kelloff, G.J., Crowell, J.A., Steele, V.E., Lubet, R.A., Malone, W.A., Boone, C.W., Kopelovich, L., Hawk, E.T., Lieberman, R. and Lawrence, J.A. (2000) Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. The Journal of Nutrition, 130, 467S-471S.
|
[11]
|
Zhao, B.L., Li, X.J., He, R.G., Cheng, S.J. and Xin, W.J. (1989) Scavenging effect of extracts of green tea and natural antioxidants on active oxygen radicals. Cell Bio- physics, 14, 175-185.
|
[12]
|
Yang, F., Lim, G.P., Begum, A.N., Ubeda, O.J., Simmons, M.R., Ambegaokar, S.S., Chen, P.P., Kayed, R., Glabe, C.G. and Frautschy, S.A. (2005) Curcumin inhibits for- mation of amyloid beta oligomers and fibrils, binds pla- ques, and reduces amyloid in vivo. The Journal of Bio- logical Chemistry, 280, 5892-5901.
doi:10.1074/jbc.M404751200
|
[13]
|
Lim, G.P., Chu, T., Yang, F., Beech, W., Frautschy, S.A. and Cole, G.M. (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. The Journal of Neuroscience, 21, 8370- 8377.
|
[14]
|
Smith, W.W., Jiang, H., Pei, Z., Tanaka, Y., Morita, H., Sawa, A., Dawson, V.L., Dawson, T.M. and Ross, C.A. (2005) Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synu- clein-induced toxicity. Human Molecular Genetics, 14, 3801-3811. doi:10.1093/hmg/ddi396
|
[15]
|
Liu, Z., Wang, X., Yu, Y., Li, X., Wang, T., Jiang, H., Ren, Q., Jiao, Y., Sawa, A., Moran, T. and Smith, W.W. (2008) A Drosophila model for LRRK2-linked parkinsonism. Proceedings of the National Academy of Sciences of United States of America, 105, 2693-2698.
doi:10.1073/pnas.0708452105
|
[16]
|
Liu, Z., Celotto, A.M., Romero, G., Wipf, P. and Palladino, M.J. (2011) Genetically encoded redox sensor identifies the role of ROS in degenerative and mitochondrial dis- ease pathogenesis. Neurobiology of Disease, 45, 362-368. doi:10.1016/j.nbd.2011.08.022
|
[17]
|
Ahmadi, F.A., Linseman, D.A., Grammatopoulos, T.N., Jones, S.M., Bouchard, R.J., Freed, C.R., Heidenreich, K.A. and Zawada, W.M. (2003) The pesticide rotenone induces caspase-3-mediated apoptosis in ventral mesen- cephalic dopaminergic neurons. Journal of Neurochemis- try, 87, 914-921. doi:10.1046/j.1471-4159.2003.02068.x
|
[18]
|
Newhouse, K., Hsuan, S.L., Chang, S.H., Cai, B., Wang, Y. and Xia, Z. (2004) Rotenone-induced apoptosis is me- diated by p38 and JNK MAP kinases in human dopa- minergic SH-SY5Y cells. Society of Toxicology, 79, 137- 146. doi:10.1093/toxsci/kfh089
|
[19]
|
Ramachandiran, S., Hansen, J.M., Jones, D.P., Richard- son, J.R. and Miller, G.W. (2007) Divergent mechanisms of paraquat, MPP+, and rotenone toxicity: Oxidation of thioredoxin and caspase-3 activation. Society of Toxico- logy, 95, 163-171. doi:10.1093/toxsci/kfl125
|
[20]
|
Leung, K.W., Yung, K.K., Mak, N.K., Chan, Y.S., Fan, T.P. and Wong, R.N. (2007) Neuroprotective effects of ginsenoside-Rg1 in primary nigral neurons against rote- none toxicity. Neuropharmacology, 52, 827-835.
doi:10.1016/j.neuropharm.2006.10.001
|
[21]
|
Dexter, D.T., Carter, C.J., Wells, F.R., Javoy-Agid, F., Agid, Y., Lees, A., Jenner, P. and Marsden, C.D. (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. Journal of Neurochemistry, 52, 381- 389. doi:10.1111/j.1471-4159.1989.tb09133.x
|
[22]
|
Sian, J., Dexter, D.T., Lees, A.J., Daniel, S., Agid, Y., Javoy-Agid, F., Jenner, P. and Marsden, C.D. (1994) Al- terations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Annals of Neurology, 36, 348-355.
doi:10.1002/ana.410360305
|
[23]
|
Giasson, B.I., Duda, J.E., Murray, I.V., Chen, Q., Souza, J.M., Hurtig, H.I., Ischiropoulos, H., Trojanowski, J.Q. and Lee, V.M. (2000) Oxidative damage linked to neu- rodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science, 290, 985-989.
doi:10.1126/science.290.5493.985
|
[24]
|
Tabner, B.J., Turnbull, S., El-Agnaf, O.M. and Allsop, D. (2002) Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer’s disease and Par- kinson’s disease. Free Radical Biology and Medicine 32, 1076-1083. doi:10.1016/S0891-5849(02)00801-8
|
[25]
|
Maguire-Zeiss, K.A., Short, D.W. and Federoff, H.J. (2005) Synuclein, dopamine and oxidative stress: Co-con- spirators in Parkinson’s disease? Molecular Brain Re- search, 134, 18-23.
doi:10.1016/j.molbrainres.2004.09.014
|
[26]
|
Alam, Z.I., Jenner, A., Daniel, S.E., Lees, A.J., Cairns, N., Marsden, C.D., Jenner, P. and Halliwell, B. (1997) Oxida- tive DNA damage in the parkinsonian brain: An apparent selective increase in 8-hydroxyguanine levels in substan- tia nigra. Journal of Neurochemistry, 69, 1196-1203.
doi:10.1046/j.1471-4159.1997.69031196.x
|
[27]
|
Alam, Z.I., Daniel, S.E., Lees, A.J., Marsden, D.C., Jenner, P. and Halliwell, B. (1997) A generalised increase in protein carbonyls in the brain in Parkinson’s but not in- cidental Lewy body disease. Journal of Neurochemistry, 69, 1326- 1329.
doi:10.1046/j.1471-4159.1997.69031326.x
|
[28]
|
Hasegawa, E., Takeshige, K., Oishi, T., Murai, Y. and Minakami, S. (1990) 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochemical and Bio- physical Research Communications, 170, 1049-1055.
doi:10.1016/0006-291X(90)90498-C
|
[29]
|
Lotharius, J. and O’Malley, K.L. (2000) The parkinson- ism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. The Journal of Biological Chemistry, 275, 38581- 38588. doi:10.1074/jbc.M005385200
|
[30]
|
Cassarino, D.S., Fall, C.P., Swerdlow, R.H., Smith, T.S., Halvorsen, E.M., Miller, S.W., Parks, J.P., Parker, W.D., Jr. and Bennett, J.P., Jr. (1997) Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson’s disease. Biochimica et Biophysica Acta, 1362, 77-86.
doi:10.1016/S0925-4439(97)00070-7
|
[31]
|
Votyakova, T.V. and Reynolds, I.J. (2001) DeltaPsi(m)- Dependent and -independent production of reactive oxygen species by rat brain mitochondria. Journal of Neuro- chemistry, 79, 266-277.
doi:10.1046/j.1471-4159.2001.00548.x
|
[32]
|
Hensley, K., Pye, Q.N., Maidt, M.L., Stewart, C.A., Rob- inson, K.A., Jaffrey, F. and Floyd, R.A. (1998) Interaction of alpha-phenyl-N-tert-butyl nitrone and alternative elec- tron acceptors with complex I indicates a substrate reduc- tion site upstream from the rotenone binding site. Journal of Neurochemistry, 71, 2549-2557.
doi:10.1046/j.1471-4159.1998.71062549.x
|
[33]
|
Martin-Aragon, S., Benedi, J.M. and Villar, A.M. (1997) Modifications on antioxidant capacity and lipid peroxida- tion in mice under fraxetin treatment. Journal of Phar- macy and Pharmacology, 49, 49-52.
doi:10.1111/j.2042-7158.1997.tb06751.x
|
[34]
|
Sreejayan and Rao, M.N. (1997) Nitric oxide scavenging by curcuminoids. Journal of Pharmacy and Pharmacology, 49, 105-107.
doi:10.1111/j.2042-7158.1997.tb06761.x
|
[35]
|
Liu, Z., Yu, Y., Li, X., Ross, C.A. and Smith, W.W. (2011) Curcumin protects against A53T alpha-synuclein-induced toxicity in a PC12 inducible cell model for Parkinsonism. Pharmacological Research, 63, 439-444.
doi:10.1016/j.phrs.2011.01.004
|
[36]
|
Yang, D., Li, T., Liu, Z., Arbez, N., Yan, J., Moran, T.H., Ross, C.A. and Smith, W.W. (2012) LRRK2 kinase acti- vity mediates toxic interactions between genetic mutation and oxidative stress in a Drosophila model: Suppression by curcumin. Neurobiology of Disease, 47, 385-392.
doi:10.1016/j.nbd.2012.05.020
|
[37]
|
Wang, X., Qin, Z.H., Leng, Y., Wang, Y., Jin, X., Chase, T.N. and Bennett, M.C. (2002) Prostaglandin A1 inhibits rotenone-induced apoptosis in SH-SY5Y cells. Journal of Neurochemistry, 83, 1094-1102.
doi:10.1046/j.1471-4159.2002.01224.x
|
[38]
|
Chainani-Wu, N. (2003) Safety and anti-inflammatory activity of curcumin: A component of tumeric (Curcuma longa). Journal of Alternative and Complementary Medi- cine, 9, 161-168. doi:10.1089/107555303321223035
|
[39]
|
Sharm,a R.A., Euden, S.A., Platton, S.L., Cooke, D.N., Shafayat, A., Hewitt, H.R., Marczylo, T.H., Morgan, B., Hemingway, D. and Plummer, S.M. (2004) Phase I clini- cal trial of oral curcumin: Biomarkers of systemic activity and compliance. Clinical Cancer Research, 10, 6847- 6854.
|
[40]
|
Hsu, C.H. and Cheng, A.L. (2007) Clinical studies with curcumin. Advances in Experimental Medicine and Bio- logy, 595, 471-480. doi:10.1007/978-0-387-46401-5_21
|